Forest Laboratories news from FiercePharma
News
Earnings up, earnings down for drugmakers
A plethora of drug-and-device results today, from falling profits at Boston Scientific and Schering-Plough to higher earnings and flat sales at Merck. Here's the roundup:
Merck posted net income of Read more...
ALSO NOTED: Forest takes charge on Azor split; GSK launches Tykerb-Herceptin trials;
> Forest Laboratories will take a $44.1 million charge on termination of its deal to co-promote the hypertension drug Azor with Daiichi Sankyo. Read more...
ALSO NOTED: Kickback investigators focus on docs; GSK outsourcing digs into U.K. payroll;
> Fresh off their successful investigation into device makers' payments to doctors--which led to a total of $310 million in fines and ongoing disclosure agreements--the feds are turning to the Read more...
Pfizer's Lyrica booms on iffy diagnosis
Is fibromyalgia an ill-gotten label that could only benefit drug companies? Or is it a real disease that needs treatment? Judging by the abrupt rise in prescriptions for the Pfizer drug Lyrica Read more...
ALSO NOTED: Canada's drug market slowing; GSK files for Promacta approval;
> The Canadian pharma market has slowed to a growth level of 6 percent to 6.5 percent, down from a five-year average of 8.4 percent. Read more...
SPOTLIGHT: FDA approves Forest's new beta-blocker
Forest Laboratories got the FDA's nod for its blood pressure remedy Bystolic, which it makes in partnership with Mylan. Read more...
ALSO NOTED: Japan to get Roche's Tarceva next week; Barr sues two generics makers over Seasonale;
> Roche's Japanese unit Chugai Pharmaceutical is preparing to launch the lung-cancer drug Tarceva, approved in Japan in October for treatment of the non-small cell form of the disease. Read more...
ALSO NOTED: Watson gets OK to sell generic pain drug; Merck adds Reuters CEO to its board
> Watson Pharmaceutical got the FDA's blessing to sell its generic version of Combunox, a short-term pain-management drug made by Forest Laboratories. Read more...
ALSO NOTED: Levaquin gets FDA thumbs up for UTIs; Angiotech settles patent fight with J&J subsidiary;
> Angiotech Pharmaceuticals says it's settling its patent battle with Conor Medsystems over the paclitaxel stent. Conor is a Johnson & Johnson subsidiary. Read more...
Forest Labs gets Lexapro protection
How does Forest Labs spell relief? P-A-T-E-N-T. A federal court has validated the company's Lexapro protection, safeguarding that blockbuster antidepressant and antianxiety drug through 2012. The Read more...
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets